CFDA正式发布管理办法!落实医疗器械临床试验机构由“资质认定”改为“备案管理”

2017-08-05 佚名 CFDA

按照《国务院关于修改〈医疗器械监督管理条例〉的决定》(中华人民共和国国务院令第680号)的要求,医疗器械临床试验机构由资质认定改为备案管理。8月4日晚,CFDA正式印发了《医疗器械临床试验机构条件和备案管理办法(征求意见稿)》。

按照《国务院关于修改〈医疗器械监督管理条例〉的决定》(中华人民共和国国务院令第680号)的要求,医疗器械临床试验机构由资质认定改为备案管理。8月4日晚,CFDA正式印发了《医疗器械临床试验机构条件和备案管理办法(征求意见稿)》。

各省、自治区、直辖市食品药品监督管理局,有关单位:

按照《国务院关于修改〈医疗器械监督管理条例〉的决定》(中华人民共和国国务院令第680号)的要求,医疗器械临床试验机构由资质认定改为备案管理。为做好相关贯彻落实工作,国家食品药品监管总局医疗器械注册司组织起草了《医疗器械临床试验机构条件和备案管理办法(征求意见稿)》,现公开征求意见,请你单位组织研究,于2017年8月25日前反馈意见和建议。

各省、自治区、直辖市食品药品监督管理局组织汇总辖区内医疗机构和相关企业意见,并将书面意见和电子版反馈我司。其他单位或人员的意见可以电子邮件或传真方式反馈。

联 系 人:程锦,王晓光

联系电话:010-88331453,88331463

传真电话:010-88331443

电子邮箱:mdct @cfda.gov.cn

附件:医疗器械临床试验机构条件和备案管理办法(征求意见稿)

食品药品监管总局器械注册司

2017年8月4日

医疗器械临床试验机构条件和备案管理办法

附:(征求意见稿)

第一章 总 则

第一条 为了加强和规范医疗器械临床试验机构管理,根据《医疗器械监督管理条例》的规定,制定本办法。

第二条 本办法所指的医疗器械临床试验机构备案,是指医疗器械临床试验机构按照程序、条件和要求,将机构概况、专业技术水平、组织管理能力、伦理审查能力等信息提交食品药品监督管理部门进行存档、备查的过程。

第三条 本办法适用于在中华人民共和国境内开展医疗器械临床试验的机构备案管理工作。

第二章 备案条件

第四条 医疗器械临床试验机构应当具备开展医疗器械临床试验相应的专业技术水平、组织管理能力、伦理审查能力等以下条件:

(一)具有医疗机构执业资格;

(二)具有二级甲等以上资质;

(三)承担需进行临床试验审批的第三类医疗器械临床试验的,应为三级甲等医疗机构;

(四)具有医疗器械临床试验管理部门,配备适宜的管理人员、办公条件,并具有对医疗器械临床试验的组织管理和质量控制能力;

(五)具有符合医疗器械临床试验质量管理规范要求的伦理委员会;

(六)具有医疗器械临床试验管理制度和标准操作规程;

(七)具有与办理备案专业相关医疗器械相适应的诊疗科目和能够承担医疗器械临床试验的人员;

(八)医疗器械临床试验主要研究者应当具有高级职称,参加过3个以上医疗器械临床试验,办理备案专业应与医疗机构执业许可诊疗科目一致;

(九)已开展相关医疗业务,能够满足医疗器械临床试验所需的受试人群要求等;

(十)具有防范和处理医疗器械临床试验中突发事件和严重不良事件的应急机制和处置能力;

(十一)国家食品药品监督管理总局、国家卫生和计划生育委员会规定的其他条件。

第五条 承担体外诊断试剂临床试验的血液中心和中心血站、设区的市级以上疾病预防控制机构等非医疗机构,应当至少具备以下条件:

(一)具有相应业务主管部门发放的机构资质证明文件;

(二)具有体外诊断试剂临床试验的管理部门,配备相应人员、办公条件,并具有对体外诊断试剂临床试验的组织管理和质量控制能力;

(三)能够开展伦理审查工作;

(四)具有体外诊断试剂临床试验管理制度和标准操作规程;

(五)具有与办理专业相关体外诊断试剂相适应的诊疗科目和能够承担临床试验的人员;

(六)临床试验主要研究者应当具有高级职称,办理备案专业应与本机构业务范围一致;

(七)已开展相关业务,能够满足体外诊断试剂临床试验所需的受试人群要求等;

(八)具有防范和处理医疗器械临床试验中突发事件和严重不良事件的应急机制和处置能力;

(九)国家食品药品监督管理总局、国家卫生和计划生育委员会规定的其他条件。

第三章 备案程序

第六条 国家食品药品监督管理总局组织建立医疗器械临床试验机构备案管理信息系统(以下简称备案系统),用于开展医疗器械临床试验机构备案管理工作。

第七条 医疗器械临床试验机构应当根据本办法的要求对本单位是否具备医疗器械临床试验条件和能力进行评估,并自行在备案系统中备案。

第八条 医疗器械临床试验机构应当按照要求,在备案系统中如实填写以下内容:

(一)机构名称、机构性质、地址、联系方式;

(二)机构级别、规模概况,包括床位、人员配备、建筑面积、医疗设备、注册资金等;

(三)拟开展医疗器械临床试验的专业及主要研究者概况;

(四)医疗器械临床试验管理部门负责人和联系方式;

(五)提交包含如下内容的自查报告:

1. 临床试验管理部门概况、人员介绍、管理制度、标准操作规程等;

2. 伦理委员会或伦理审查工作概况,包括人员、制度等;

3. 医疗器械临床试验质量管理体系建立运行概况;

4. 临床试验管理部门人员、研究者的医疗器械临床试验相关法规和专业知识培训情况;

5. 防范和处理医疗器械临床试验中突发事件、严重不良事件的应急机制和处置能力情况;

6. 既往开展医疗器械临床试验的情况;

7. 其他需要说明的情况。

第九条 医疗器械临床试验机构应按照备案系统要求,上传医疗机构执业资格许可证照、医疗机构级别证明文件、其他机构资质证明文件和资料符合性声明等材料。

第十条 国家食品药品监督管理总局通过备案系统发放备案号,并及时公布医疗器械临床试验机构名称、地址、联系人、联系方式和主要研究者等有关备案信息供公众查询。

医疗器械临床试验机构办理备案后可以承担医疗器械临床试验。

第十一条 医疗器械临床试验机构名称、机构负责人员、地址、伦理委员会、医疗器械临床试验专业和主要研究者等备案信息发生变化时,医疗器械临床试验机构应当登陆备案系统,在线填写相关信息变更情况。

第十二条 医疗器械临床试验机构备案后,应当在每年1月31日前在线提交本单位上一年度开展医疗器械临床试验工作总结报告。

第十三条 医疗器械临床试验机构决定不再开展医疗器械临床试验的,应登陆备案系统,取消备案。

第四章 监督管理

第十四条 省级食品药品监督管理部门应当每年定期将本行政区域医疗器械临床试验机构备案的相关信息通报同级卫生计生行政部门。

第十五条 省级食品药品监督管理部门、卫生计生行政部门应按照各自监管职责,加强对本行政区域医疗器械临床试验机构的监督管理和信息沟通。对发现的违法违规行为,按照《医疗器械监督管理条例》及其他相关法规规定组织查处。发现隐瞒有关情况或者提供虚假材料办理临床试验机构备案的,或者存在缺陷、不适宜继续承担临床试验的临床试验机构,报告国家食品药品监督管理总局、国家卫生和计划生育委员会。

医疗器械临床试验机构应当对相关监督管理工作予以配合。

第十六条 隐瞒有关情况或者提供虚假材料办理临床试验机构备案的,或者存在缺陷、不适宜继续承担临床试验的临床试验机构,国家食品药品监督管理总局取消其机构或相关专业的备案信息,通报国家卫生和计划生育委员会,并进行公告。

对隐瞒有关情况或者提供虚假材料被取消备案的医疗机构或者相关专业,三年内不接受其备案;对存在缺陷、不适宜继续承担临床试验被取消备案的临床机构或者相关专业,一年内不接受其备案。

第十七条 医疗器械临床试验机构的备案信息涉及国家机密、商业秘密或者个人隐私的,应当符合《中华人民共和国保守国家秘密法》及其他相关法律法规的规定。

第五章 附 则

第十八条 医疗器械临床试验机构备案号格式为:4位年代号+5位顺序编号。

第十九条 食品药品监管部门实施临床试验机构备案和监督管理,不得收取任何费用。

第二十条 本办法自2017年X月X日起施行。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=906892, encodeId=546b90689292, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc3c5443368, createdName=水木相生, createdTime=Thu Dec 10 23:06:18 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890645, encodeId=bcd41890645ad, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Jan 29 09:01:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010984, encodeId=205d2010984d5, content=<a href='/topic/show?id=192c424e930' target=_blank style='color:#2F92EE;'>#备案管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42479, encryptionId=192c424e930, topicName=备案管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Sep 24 23:01:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955883, encodeId=3b931955883ab, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Tue Feb 06 12:01:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590911, encodeId=622b15909111f, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Mon Aug 07 08:01:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230566, encodeId=2849230566e8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 06 07:10:55 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230500, encodeId=ddd7230500be, content=学习过了,很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Aug 06 00:28:37 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
    2020-12-10 水木相生

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=906892, encodeId=546b90689292, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc3c5443368, createdName=水木相生, createdTime=Thu Dec 10 23:06:18 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890645, encodeId=bcd41890645ad, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Jan 29 09:01:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010984, encodeId=205d2010984d5, content=<a href='/topic/show?id=192c424e930' target=_blank style='color:#2F92EE;'>#备案管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42479, encryptionId=192c424e930, topicName=备案管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Sep 24 23:01:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955883, encodeId=3b931955883ab, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Tue Feb 06 12:01:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590911, encodeId=622b15909111f, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Mon Aug 07 08:01:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230566, encodeId=2849230566e8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 06 07:10:55 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230500, encodeId=ddd7230500be, content=学习过了,很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Aug 06 00:28:37 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
    2018-01-29 stfoxst
  3. [GetPortalCommentsPageByObjectIdResponse(id=906892, encodeId=546b90689292, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc3c5443368, createdName=水木相生, createdTime=Thu Dec 10 23:06:18 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890645, encodeId=bcd41890645ad, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Jan 29 09:01:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010984, encodeId=205d2010984d5, content=<a href='/topic/show?id=192c424e930' target=_blank style='color:#2F92EE;'>#备案管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42479, encryptionId=192c424e930, topicName=备案管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Sep 24 23:01:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955883, encodeId=3b931955883ab, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Tue Feb 06 12:01:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590911, encodeId=622b15909111f, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Mon Aug 07 08:01:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230566, encodeId=2849230566e8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 06 07:10:55 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230500, encodeId=ddd7230500be, content=学习过了,很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Aug 06 00:28:37 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
    2017-09-24 yahu
  4. [GetPortalCommentsPageByObjectIdResponse(id=906892, encodeId=546b90689292, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc3c5443368, createdName=水木相生, createdTime=Thu Dec 10 23:06:18 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890645, encodeId=bcd41890645ad, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Jan 29 09:01:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010984, encodeId=205d2010984d5, content=<a href='/topic/show?id=192c424e930' target=_blank style='color:#2F92EE;'>#备案管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42479, encryptionId=192c424e930, topicName=备案管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Sep 24 23:01:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955883, encodeId=3b931955883ab, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Tue Feb 06 12:01:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590911, encodeId=622b15909111f, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Mon Aug 07 08:01:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230566, encodeId=2849230566e8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 06 07:10:55 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230500, encodeId=ddd7230500be, content=学习过了,很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Aug 06 00:28:37 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=906892, encodeId=546b90689292, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc3c5443368, createdName=水木相生, createdTime=Thu Dec 10 23:06:18 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890645, encodeId=bcd41890645ad, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Jan 29 09:01:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010984, encodeId=205d2010984d5, content=<a href='/topic/show?id=192c424e930' target=_blank style='color:#2F92EE;'>#备案管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42479, encryptionId=192c424e930, topicName=备案管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Sep 24 23:01:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955883, encodeId=3b931955883ab, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Tue Feb 06 12:01:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590911, encodeId=622b15909111f, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Mon Aug 07 08:01:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230566, encodeId=2849230566e8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 06 07:10:55 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230500, encodeId=ddd7230500be, content=学习过了,很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Aug 06 00:28:37 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
    2017-08-07 cenghis
  6. [GetPortalCommentsPageByObjectIdResponse(id=906892, encodeId=546b90689292, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc3c5443368, createdName=水木相生, createdTime=Thu Dec 10 23:06:18 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890645, encodeId=bcd41890645ad, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Jan 29 09:01:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010984, encodeId=205d2010984d5, content=<a href='/topic/show?id=192c424e930' target=_blank style='color:#2F92EE;'>#备案管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42479, encryptionId=192c424e930, topicName=备案管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Sep 24 23:01:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955883, encodeId=3b931955883ab, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Tue Feb 06 12:01:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590911, encodeId=622b15909111f, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Mon Aug 07 08:01:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230566, encodeId=2849230566e8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 06 07:10:55 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230500, encodeId=ddd7230500be, content=学习过了,很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Aug 06 00:28:37 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
    2017-08-06 130****4638

    学习了谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=906892, encodeId=546b90689292, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc3c5443368, createdName=水木相生, createdTime=Thu Dec 10 23:06:18 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890645, encodeId=bcd41890645ad, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Jan 29 09:01:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010984, encodeId=205d2010984d5, content=<a href='/topic/show?id=192c424e930' target=_blank style='color:#2F92EE;'>#备案管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42479, encryptionId=192c424e930, topicName=备案管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Sep 24 23:01:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955883, encodeId=3b931955883ab, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Tue Feb 06 12:01:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590911, encodeId=622b15909111f, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Mon Aug 07 08:01:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230566, encodeId=2849230566e8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 06 07:10:55 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230500, encodeId=ddd7230500be, content=学习过了,很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Aug 06 00:28:37 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
    2017-08-06 明天会更好!

    学习过了,很好!

    0

相关资讯

CFDA拟放宽II、III类注册检验要求,企业可以自主检验

根据械注[2017] 165号文件,总局医疗器械注册管理司将调整医疗器械检验相关工作。这次调整总体来说对企业是利好的,也是我国医疗器械注册监管迈向国际化的一步。

临床研究的春天到了?—关于CFDA 53号文

认证改为备案,将简化流程,释放大量机构、资源,比如二三线城市?

CDE与山东省药监局达成战略合作 共同提升药品审评能力

为加快推进药品审评审批制度改革,促进国家总局及省局技术审评优势互补,共同推进药品技术审评能力建设,5月26日,国家食品药品监督管理总局药审中心与山东省食品药品监督管理局签署战略合作协议。总局副局长孙咸泽出席签字仪式并讲话。

GMP等认证将取消 落地后如何监管?

近日,有消息称,国家食品药品监督管理总局副局长吴浈在刚刚结束的全国食品药品监督管理工作座谈会上提出,今后取消GMP、GCP、GLP、GSP,实现两证合一,不再发认证证书。

CFDA全面接轨FDA,年底试行药品电子通用技术文档系统(eCTD)

2017年5月30日,CFDA药品审评中心的工作人员却并未休息,两部关于eCTD(药品电子技术通用技术文档)的征求意见稿选择在这一天发布,分别是《药品电子通用技术文档机构(征求意见稿)》以及《化学仿制药电子通用技术文档申报指导原则(征求意见稿)》。这也是既毕井泉局长在2月27日国务院新闻发布会上透露将建立eCTD系统并争取2017年底能够实现按新系统实行电子申报和审评以来,在推行eCTD进程方

中药饮片成黑榜常客 CFDA年内曾10次点名

近日,国家食药监总局发布了《关于12批次中药饮片不合格的通告》,经中国食品药品检定研究院检验,标示为吉林省元力药业有限公司等10家企业生产的12批次中药饮片不合格。